Explorative investigation of vascular endothelial growth factor receptor expression in primary ovarian cancer and its clinical relevance

Gynecologic Oncology

Volumn 133, Issue 3, 2014, Pages 467-472

  Wimberger, Pauline ^a,b   Chebouti, Issam ^a   Kasimir Bauer, Sabine ^a   Lachmann, Robert ^b   Kuhlisch, Eberhard ^b   Kimmig, Rainer ^a   Süleyman, Ergün ^c   Kuhlmann, Jan Dominik ^a,b  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^c UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Angiogenesis; Bevacizumab; Disseminated tumor cells; Ovarian cancer; Vascular endothelial growth factor receptor

Indexed keywords

VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ADULT; AGED; ANGIOGENESIS; ARTICLE; ASCITES; BLOOD VESSEL WALL; BONE MARROW; CELL STRUCTURE; CYTOREDUCTIVE SURGERY; FEMALE; HUMAN; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; METASTASIS; OUTCOME ASSESSMENT; OVARY CANCER; PRIMARY TUMOR; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; STAINING; STROMA; TUMOR VOLUME; VASCULARIZATION; VERY ELDERLY;

ANGIOGENESIS; BEVACIZUMAB; DISSEMINATED TUMOR CELLS; OVARIAN CANCER; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR;

ADENOCARCINOMA, MUCINOUS; ADULT; AGED; AGED, 80 AND OVER; BONE MARROW; BONE MARROW NEOPLASMS; CYSTADENOCARCINOMA, SEROUS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM, RESIDUAL; NEOPLASTIC CELLS, CIRCULATING; OVARIAN NEOPLASMS; PROGNOSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3; YOUNG ADULT;

EID: 84901670679     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2014.03.574     Document Type: Article

References (40)

1. R.J. Black, F. Bray, J. Ferlay, and D.M. Parkin Cancer incidence and mortality in the European Union: cancer registry data and estimates of national incidence for 1990 Eur J Cancer 33 1997 1075 1107
2. A. du Bois, M. Quinn, T. Thigpen, J. Vermorken, E. Avall-Lundqvist, and M. Bookman et al. 2004 Consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004) Ann Oncol 16 Suppl. 8 2005 viii7 viii12
3. A. du Bois, A. Reuss, E. Pujade-Lauraine, P. Harter, I. Ray-Coquard, and J. Pfisterer Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO) Cancer 115 2009 1234 1244
4. P. Wimberger, M. Wehling, N. Lehmann, R. Kimmig, B. Schmalfeldt, and A. Burges et al. Influence of residual tumor on outcome in ovarian cancer patients with FIGO stage IV disease: an exploratory analysis of the AGO-OVAR (Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group) Ann Surg Oncol 17 2010 1642 1648
5. M.A. Bookman Extending the platinum-free interval in recurrent ovarian cancer: the role of topotecan in second-line chemotherapy Oncologist 4 1999 87 94
6. L.P. Martin, and R.J. Schilder Management of recurrent ovarian carcinoma: current status and future directions Semin Oncol 36 2009 112 125
7. A.T. Byrne, L. Ross, J. Holash, M. Nakanishi, L. Hu, and J.I. Hofmann et al. Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model Clin Cancer Res 9 2003 5721 5728
8. N. Ferrara VEGF and the quest for tumour angiogenesis factors Nat Rev Cancer 2 2002 795 803
9. F.A. Raja, J.M. Hook, and J.A. Ledermann Biomarkers in the development of anti-angiogenic therapies for ovarian cancer Cancer Treat Rev 38 2012 662 672
10. L.M. Ellis, and D.J. Hicklin VEGF-targeted therapy: mechanisms of anti-tumour activity Nat Rev Cancer 8 2008 579 591
11. B.C. Cooper, J.M. Ritchie, C.L. Broghammer, J. Coffin, J.I. Sorosky, and R.E. Buller et al. Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer Clin Cancer Res 8 2002 3193 3197
12. S.K. Kassim, E.M. El-Salahy, S.T. Fayed, S.A. Helal, T. Helal, and D. Azzam Eel et al. Vascular endothelial growth factor and interleukin-8 are associated with poor prognosis in epithelial ovarian cancer patients Clin Biochem 37 2004 363 369
13. T.J. Perren, A.M. Swart, J. Pfisterer, J.A. Ledermann, E. Pujade-Lauraine, and G. Kristensen et al. A phase 3 trial of bevacizumab in ovarian cancer N Engl J Med 365 2011 2484 2496
14. R.A. Burger, M.F. Brady, M.A. Bookman, G.F. Fleming, B.J. Monk, and H. Huang et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer N Engl J Med 365 2011 2473 2483
15. A. du Bois, A. Floquet, J.W. Kim, J. Rau, J.M. Del Campo, and M. Friedlander et al. Randomized, double-blind, phase III trial of pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (AEOC): results of an international Intergroup trial (AGO-OVAR16) J Clin Oncol 31 2013 [Suppl.; abstr LBA5503]
16. C. Aghajanian, S.V. Blank, B.A. Goff, P.L. Judson, M.G. Teneriello, and A. Husain et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer J Clin Oncol 30 2012 2039 2045
17. E. Pujade-Lauraine, F. Hilpert, B. Weber, A. Reuss, A. Poveda, and G. Kristensen et al. AURELIA: a randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC) J Clin Oncol 30 2012 [Suppl.; abstr LBA5002]
18. P.J. Paley, K.A. Staskus, K. Gebhard, D. Mohanraj, L.B. Twiggs, and L.F. Carson et al. Vascular endothelial growth factor expression in early stage ovarian carcinoma Cancer 80 1997 98 106
19. S. Yamamoto, I. Konishi, M. Mandai, H. Kuroda, T. Komatsu, and K. Nanbu et al. Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levels Br J Cancer 76 1997 1221 1227
20. D. Tilki, N. Kilic, S. Sevinc, F. Zywietz, C.G. Stief, and S. Ergun Zone-specific remodeling of tumor blood vessels affects tumor growth Cancer 110 2007 2347 2362
21. S. Ergun, N. Kilik, G. Ziegeler, A. Hansen, P. Nollau, and J. Gotze et al. CEA-related cell adhesion molecule 1: a potent angiogenic factor and a major effector of vascular endothelial growth factor Mol Cell 5 2000 311 320
22. N. Kilic, and S. Ergun Methods to evaluate the formation and stabilization of blood vessels and their role in tumor growth and metastasis Methods Mol Med 58 2001 125 148
23. T. Fehm, S. Braun, V. Muller, W. Janni, G. Gebauer, and C. Marth et al. A concept for the standardized detection of disseminated tumor cells in bone marrow from patients with primary breast cancer and its clinical implementation Cancer 107 2006 885 892
24. E. Borgen, B. Naume, J.M. Nesland, G. Kvalheim, K. Beiske, and O. Fodstad et al. Standardization of the immunocytochemical detection of cancer cells in BM and blood: I. Establishment of objective criteria for the evaluation of immunostained cells Cytotherapy 1 1999 377 388
25. N.R. Smith, D. Baker, N.H. James, K. Ratcliffe, M. Jenkins, and S.E. Ashton et al. Vascular endothelial growth factor receptors VEGFR-2 and VEGFR-3 are localized primarily to the vasculature in human primary solid cancers Clin Cancer Res 16 2010 3548 3561
26. S. Banerjee, S. Mehta, I. Haque, K. Sengupta, K. Dhar, and S. Kambhampati et al. VEGF-A165 induces human aortic smooth muscle cell migration by activating neuropilin-1-VEGFR1-PI3K axis Biochemistry 47 2008 3345 3351
27. I. Helfrich, I. Scheffrahn, S. Bartling, J. Weis, V. von Felbert, and M. Middleton et al. Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma J Exp Med 207 2010 491 503
28. P. Weisshardt, T. Trarbach, J. Durig, A. Paul, H. Reis, and D. Tilki et al. Tumor vessel stabilization and remodeling by anti-angiogenic therapy with bevacizumab Histochem Cell Biol 137 2012 391 401
29. W.A. Spannuth, A.M. Nick, N.B. Jennings, G.N. Armaiz-Pena, L.S. Mangala, and C.G. Danes et al. Functional significance of VEGFR-2 on ovarian cancer cells Int J Cancer 124 2009 1045 1053
30. R.S. Watnick The role of the tumor microenvironment in regulating angiogenesis Cold Spring Harb Perspect Med 2 2012 a006676
31. I. Sher, S.A. Adham, J. Petrik, and B.L. Coomber Autocrine VEGF-A/KDR loop protects epithelial ovarian carcinoma cells from anoikis Int J Cancer 124 2009 553 561
32. R.K. Jain, D.G. Duda, C.G. Willett, D.V. Sahani, A.X. Zhu, and J.S. Loeffler et al. Biomarkers of response and resistance to antiangiogenic therapy Nat Rev Clin Oncol 6 2009 327 338
33. D. Klasa-Mazurkiewicz, M. Jarzab, T. Milczek, B. Lipinska, and J. Emerich Clinical significance of VEGFR-2 and VEGFR-3 expression in ovarian cancer patients Pol J Pathol 62 2011 31 40
34. B. Aktas, S. Kasimir-Bauer, M. Heubner, R. Kimmig, and P. Wimberger Molecular profiling and prognostic relevance of circulating tumor cells in the blood of ovarian cancer patients at primary diagnosis and after platinum-based chemotherapy Int J Gynecol Cancer 21 2011 822 830
35. S. Braun, C. Schindlbeck, F. Hepp, W. Janni, C. Kentenich, and G. Riethmuller et al. Occult tumor cells in bone marrow of patients with locoregionally restricted ovarian cancer predict early distant metastatic relapse J Clin Oncol 19 2001 368 375
36. T. Fehm, M. Banys, B. Rack, W. Janni, C. Marth, and C. Blassl et al. Pooled analysis of the prognostic relevance of disseminated tumor cells in the bone marrow of patients with ovarian cancer Int J Gynecol Cancer 23 2013 839 845
37. N. Nishida, H. Yano, K. Komai, T. Nishida, T. Kamura, and M. Kojiro Vascular endothelial growth factor C and vascular endothelial growth factor receptor 2 are related closely to the prognosis of patients with ovarian carcinoma Cancer 101 2004 1364 1374
38. N.C. Kappas, G. Zeng, J.C. Chappell, J.B. Kearney, S. Hazarika, and K.G. Kallianos et al. The VEGF receptor Flt-1 spatially modulates Flk-1 signaling and blood vessel branching J Cell Biol 181 2008 847 858
39. B.M. Lichtenberger, P.K. Tan, H. Niederleithner, N. Ferrara, P. Petzelbauer, and M. Sibilia Autocrine VEGF signaling synergizes with EGFR in tumor cells to promote epithelial cancer development Cell 140 2010 268 279
40. J.S. Wey, F. Fan, M.J. Gray, T.W. Bauer, M.F. McCarty, and R. Somcio et al. Vascular endothelial growth factor receptor-1 promotes migration and invasion in pancreatic carcinoma cell lines Cancer 104 2005 427 438